Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Management of MLL-rearranged ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.10.18
Views: 946

Prof Rob Pieters - Princess Maxima Centre for paediatric oncology (UU), Utrecht, Netherlands

Prof Rob Pieters talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the management of MLL-rearranged ALL.

Prof Pieters discusses what these rearrangements mean for prognosis and also for screening and the treatment selection.

He goes on to talk about the new targets in therapy: demethylating agents and HDAC inhibitors.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation